VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Monday morning. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald reissued an overweight rating and issued a $2.50 price target on shares of VolitionRx in a research note on Thursday, May 16th.

VolitionRx Price Performance

VNRX stock opened at $0.66 on Monday. VolitionRx has a 52-week low of $0.55 and a 52-week high of $1.54. The stock has a market cap of $54.32 million, a price-to-earnings ratio of -1.42 and a beta of 1.14. The business has a fifty day moving average of $0.69 and a two-hundred day moving average of $0.83.

VolitionRx (NYSE:VNRX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.27 million. As a group, sell-side analysts anticipate that VolitionRx will post -0.31 EPS for the current year.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently bought a new position in VolitionRx stock. Silverberg Bernstein Capital Management LLC bought a new stake in shares of VolitionRx Limited (NYSE:VNRX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx at the end of the most recent reporting period. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.